Skip to main content
    J

    Journey Medical Corp (DERM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.70
    -0.63 (-14.55%)

    Market Cap: $122.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Journey Medical Corp (DERM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Journey Medical (DERM) to earn -$0.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $77.50M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 50.0%.

    Fiscal year ending Dec 31, 2026
    -$0.13
    EPS consensus, revenue $77.50M
    Fiscal year ending Dec 31, 2027
    $0.44
    EPS consensus, revenue $116.25M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.13-$0.29 to $0.024$77.50M$75.10M to $82.37M4
    Dec 31, 2027$0.44$0.15 to $0.724$116.25M$103.50M to $134.29M4

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.00-$0.12 to $0.086$22.02M$18.82M to $27.52M6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202602
    Fiscal year ending Dec 31, 202702

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a profit of $0.07 to a loss.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.13-$0.13-$0.04-$0.04$0.07N/A
    Fiscal year ending Dec 31, 2027$0.44$0.44$0.68$0.68$1.04-57.3%

    Frequently Asked Questions About DERM

    What is the DERM stock forecast?

    Consensus analyst estimates put Journey Medical's EPS at -$0.13 for the fiscal year ending Dec 31, 2026, on revenue of $77.50M. The consensus rating from 4 analysts is Buy.

    How do analysts rate DERM stock?

    Of 4 analysts covering Journey Medical, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from DERM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.13, with estimates from -$0.29 to $0.02 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.44, with estimates from $0.15 to $0.72 from 4 analysts.

    What revenue do analysts expect from Journey Medical next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $77.50M, with estimates from $75.10M to $82.37M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $116.25M, with estimates from $103.50M to $134.29M.

    How many analysts cover DERM?

    4 analysts rate Journey Medical stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.